Analysis

Investors have their eyes fixed on July 23, the date SAP will release second-quarter results after months of sliding share...

Palantir’s Summer of Contradictions: Record Contracts, a CEO Feud, and a Stock Going Nowhere

Palantir’s shares ended the week at €111.02, down 1.7% on Friday and 1.12% lower over the past seven days. Since...

Sellas Life Sciences Holds Its Breath as a Leukemia Trial Nears the Finish Line

The stock of Sellas Life Sciences has become a high-wire act, driven by a single, narrowing countdown: just two more...

Valneva’s Binary Outlook: A Broken Commercial Business Versus a Potentially Blockbuster Pipeline

For investors in Valneva, the gap between hope and reality has rarely been wider. The French biotech’s stock ended last...

Lam Research: Analyst Price Targets Soar to $425 as the Stock Holds Its Breath

The semiconductor equipment maker Lam Research finds itself in an odd spot. Its shares have barely budged over the past...

Ocugen’s 673% Analyst Upside Hinges on a Tight Window of Clinical Data and Regulatory Submissions

A €10 price target with the stock trading at €1.29. That 673% gap isn't a typo — it's the distance...

Intel’s 200-Billion-Dollar Bet Leaves Stock Reeling Despite Record Analyst Targets

by Jackson Burston

Intel’s stunning 186% year-to-date surge has hit a wall, with the stock shedding nearly 12% in a single week to...

Novo Nordisk Tests Resistance Near Overbought as Buyback and Oral Wegovy Drive Sentiment

Novo Nordisk closed the week at €43.32, adding 1.29% on Friday alone, as a wave of analyst upgrades and a...

Talk of Pay: German Court Rulings and EU Rules Sap Employer Secrecy Clauses

Companies that try to silence workers about their salaries are finding such bans unenforceable. Salary is not a trade secret,...

IREN’s AI Transformation Generates Analyst Buzz – But a 97 P/E and 46% Drop From Peak Give Bulls Pause